May 17, 2020

Dassault Systèmes Living Heart Project reaches next milestones in improving patient care

Technology
Cardiology
heart disease
Catherine Sturman
2 min
Dassault Systèmes Living Heart Project
With ambitions to drive the creation and use of simulated 3D personalised hearts in the treatment, diagnosis and prevention of heart diseases, Dassault...

With ambitions to drive the creation and use of simulated 3D personalised hearts in the treatment, diagnosis and prevention of heart diseases, Dassault Systèmes has defined the milestones within its Living Heart Project.

Available through Dassault Systèmes 3DEXPERIENCE cloud platform, the project is targeted at the scientific and medical community, who seek to find faster, targeted ways to improve patient care through new partnerships. The platform offers the speed and flexibility of high-performance computing (HPC) to even the smallest medical device companies.

The Living Heart Project has grown to more than 95-member organisations worldwide including medical researchers, practitioners, device manufacturers and regulatory agencies united in a mission of open innovation to solve healthcare challenges. 

The project has supported 15 research grant proposals by providing access to the model, associated technologies and project expertise. Novel use of the model to understand heart disease and study the safety and effectiveness of medical devices has appeared in eight articles published in peer-reviewed journals to date. 

Related stories

Through the platform, any life sciences company can access a complete, on-demand HPC environment to scale up virtual testing securely and collaboratively while managing infrastructure costs.  This also crosses an important boundary toward the use of the Living Heart directly in a clinical setting.

“Medical devices need thousands of tests in the development stage,” said Joe Formicola, President and Chief Engineer, Caelynx. “With the move of the Living Heart to the cloud, effectively an unlimited number of tests of a new design can be carried out simultaneously using the simulated heart rather than one at a time, dramatically lowering the barrier to innovation, not to mention the time and cost.”

Since signing a 5-year agreement with the FDA in 2014, Dassault Systèmes will continue to align with the regulatory agency on the use of simulation and modelling to accelerate approvals. “Modelling and simulation plays a critical role in organizing diverse data sets and exploring alternate study designs. This enables safe and effective new therapeutics to advance more efficiently through the different stages of clinical trials,” Food & Drug Administration Commissioner Dr. Scott Gottlieb has said.

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article